Navigation Links
NovaVision Appoints Medical Technology Veteran Rudy Mazzocchi as Chief Executive Officer
Date:6/16/2008

BOCA RATON, Fla., June 16 /PRNewswire/ -- NovaVision today announced the appointment of Rudy Mazzocchi as its new chief executive officer. In his role, Mazzocchi is responsible for leveraging the company's novel technology to find new channels of growth to ensure that patients with impaired vision have access to NovaVision(R) Vision Restoration Therapy (VRT).

Mazzocchi has 25 years of expertise bringing new medical technologies and devices to market that address unmet clinical needs. With extensive senior management, operational and financing experience, he has served as chief executive officer and founder of many medical technology or device companies.

Most recently, he served as Managing Director of Accuitive Medical Ventures, an Atlanta-based venture capital fund that specializes in early-stage medical technology investments. Prior to that he served as chairman and interim CEO of Triton BioSystems, a company developing a nanotechnology based approach to cancer therapy and was co-founder and CEO of Image-Guided Neurologics, an early stage neurosurgical device company acquired by Medtronic in August 2005. He was also founder, president and CEO of Microvena Corporation, a public medical device company now known as "eV3". Mazzocchi holds approximately 40 medical device patents and has published numerous scientific and medical journal articles.

"I've watched NovaVision build strong momentum over the past several years and emerge as a leading company in the area of vision restoration therapy," said Mazzocchi. "I'm excited to build on the progress already established. There is recently published data confirming the neuroscience behind VRT, interest within the U.S. veteran's healthcare system for providing VRT to American soldiers, and encouraging endorsements from congressional delegates to support reimbursement efforts. Most important, I'm honored to lead the team of intelligent and passionate employees who are dedicated to improving the lives of millions of stroke and traumatic brain injury survivors living with impaired vision."

Navroze Mehta, founder of NovaVision will be vice chairman of the board of directors. "I am excited about the role Rudy will play in leading the company into the future," stated Navroze Mehta. "His outstanding experiences will allow NovaVision to continue to grow and greatly expand the accessibility to patients with impaired vision."

VRT is the only FDA-cleared, patented, non-invasive medical device that can enhance vision in people who have been left partially blind due to stroke or brain trauma and is offered at centers across the United States. Treatment consists of comprehensive diagnostic testing that allows specialists to map the seeing and non-seeing areas of vision and create a customized therapy that participants perform daily for six-to-seven months. Patients gradually improve their vision through the repeated detection of a specific pattern of optical stimulation directed at the border between the seeing and blind areas of the visual field.

About NovaVision, Inc.

NovaVision, Inc., headquartered in Boca Raton, Fla., develops and provides scientifically-based, innovative medical devices and comprehensive solutions to restore the vision of patients with neurological visual impairments. FDA-cleared in 2003, NovaVision's Vision Restoration Therapy devices work by enhancing neuroplasticity -- the brain's ability to adapt and form new connections to compensate for injury. NovaVision's diagnostic program maps areas where vision may be improved, and the therapy program targets and stimulates regions within the brain's vision-processing areas.

NovaVision VRT(R) is based on more than 10 years of research with clinical studies published in leading journals including Nature Medicine, Neurology, and The Journal of Cognitive Neuroscience. Data from a recent retrospective study identified that more than 70 percent of patients who underwent VRT for an initial six-month treatment period showed measurable improvements in their vision.

VRT is currently offered at leading neurological, eye and rehabilitation centers nationwide. For more information, please visit http://www.novavision.com or call 1.888.205.0800.

Contacts:

Ellie Kline, Edelman on behalf of NovaVision

Ph. 212-704-4528

Email: ellie.kline@edelman.com


'/>"/>
SOURCE NovaVision, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Related biology technology :

1. Applied Computational Technologies Appoints a New CEO
2. AngioGenex Appoints New CEO to Direct Development of Anti-Cancer Drugs
3. BMP Sunstone Corporation Appoints Zhiqiang Han to President and Chief Operating Officer
4. American Oriental Bioengineering Appoints Anindya Chatterjee to Chief Strategy Officer
5. Quintiles Appoints Christopher Cabell to Chief Medical and Scientific Officer
6. National Stem Cell Holding Appoints Kenneth Steiner, MD, MBA, as Chief Operating Officer
7. Signalife Appoints Lee Ehrlichman President and Chief Operating Officer
8. RainDance Appoints Kelly Chief Operating Officer
9. IntegriChain Appoints John Bailye to Its Board of Directors
10. Trius Appoints Paul Truex to Board of Directors
11. Pelikan Technologies Appoints Denny Ware to Board of Directors
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/8/2016)... ... December 08, 2016 , ... KBioBox llc announced today ... demand KbioBox developed a sophisticated “3 click” gene dditing off target analysis program ... new website, https://www.kbiobox.com/ and powered by the company’s proprietary BioEngine. ...
(Date:12/8/2016)... Dec. 8, 2016  Soligenix, Inc. (OTCQB: SNGX) ... focused on developing and commercializing products to treat ... need, announced today the long-term follow-up data from ... a first-in-class Innate Defense Regulator (IDR), in the ... neck cancer patients undergoing chemoradiation therapy (CRT).  The ...
(Date:12/8/2016)... 2016 Eutilex Co. Ltd. today announced that ... Series A financing. This financing round included participation from ... SNU Bio Angel. This new funding brings the total ... $27.7M) since its founding in 2015. ... and commercialization of its immuno-oncology programs, expand its R&D ...
(Date:12/7/2016)... ... 07, 2016 , ... A new study published in the ... treated, advanced pancreatic cancer, liquid biopsies are not yet an adequate substitute for ... blood sampling may improve the value of a blood-based test.” The study was ...
Breaking Biology Technology:
(Date:11/19/2016)... 18, 2016 Securus Technologies, a leading provider ... safety, investigation, corrections and monitoring, announced today that it ... to have an independent technology judge determine who has ... high tech/sophisticated telephone calling platform, and the best customer ... do most of what we do – which clearly ...
(Date:11/17/2016)... OF INDUSTRY, Calif. , Nov. 17, 2016  AIC announces that it has ... using NVMe storage servers in organizations that require high-performance scale-out plus high speed data transfer storage ... ... ... Setting up ...
(Date:11/15/2016)... 15, 2016  Synthetic Biologics, Inc. (NYSE MKT: ... on the gut microbiome, today announced the pricing ... of its common stock and warrants to purchase ... price to the public of $1.00 per share ... from the offering, excluding the proceeds, if any ...
Breaking Biology News(10 mins):